Program
pirfenidone
Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.
Drug pagePirfenidone: every studyMany companies study it; this page follows only the 29 they lead. All 102 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 120 open or running | phase 4since Nov 4, 2015 | Mar 24, 2004 | none ahead |
| GNI Group | 72 open or running | phase 3since Feb 26, 2019 | Nov 18, 2014 | Dec 30, 2026phase 3 · NCT07388680 |
| PureTechits history only | 52 open or running | phase 3since Dec 8, 2025 | Jan 21, 2020 | Nov 2029phase 3 · NCT07284602 |
| Overseas Pharmaceuticalsits history only | 30 open or running | phase 1since Aug 22, 2024 | Aug 22, 2024 | none ahead |
| beijing-kawin-technology-share-holding-co-ltdits history only | 10 open or running | phase 2since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| grupo-medifarma-s-a-de-c-vits history only | 10 open or running | phase 3since Jul 6, 2015 | Jul 6, 2015 | none ahead |
Also a collaborator on its studies: Clinipace Worldwide, Novotech (Australia) Pty, Shanghai Genomics and GNI-EPS Pharmaceuticals, Inc. (GNI Group).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GNI Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 18, 2014First study: phase 2 study in Radiation PneumonitisFirst studyNCT02296281 · 48 enrolled
- Feb 26, 20192 phase 3 studiesNCT03857854, NCT03856853
- Apr 2, 2019Phase 2 study in Radiation-induced Lung InjuryNCT03902509 · 126 enrolled · China
- Oct 10, 2019Phase 1 study in Renal InsufficiencyNCT04126538 · 24 enrolled · China
- Feb 17, 2022Phase 3 study in PneumoconiosisNCT05288179 · 272 planned · China
- Nov 17, 2025Phase 3 study in Radiation-induced Lung InjuryNCT07388680 · 298 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Radiation-induced Lung InjuryNCT07388680
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 GNI Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07388680Radiation-induced Lung Injury · China | 3 | Recruiting | Dec 30, 2026 | 298 |
| NCT05288179Pneumoconiosis · China | 3 | Recruiting | Sep 30, 2026 | 272 |
| NCT04126538Renal Insufficiency · China | 1 | UNKNOWN | Nov 25, 2021 | 24 |
| NCT03902509Radiation-induced Lung Injury · China | 2 | Completed | Dec 4, 2023 | 126 |
| NCT03857854Dermatomyositis Interstitial Lung Disease (Dm-ILD) · China | 3 | UNKNOWN | Feb 2021 | 152 |
| NCT03856853Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) · China | 3 | UNKNOWN | Feb 10, 2021 | 144 |
| NCT02296281Radiation Pneumonitis | 2 | UNKNOWN | Jun 2016 | 48 |
How it is read
Names in the registry
- “Pirfenidone”, 26 entries
- “Pirfenidone Modified-Release Tablets”, 4 entries
- “Deupirfenidone”, 3 entries
- “pirfenidone capsule”, 2 entries
- “pirfenidone”, 2 entries
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 21 studies
- Lung Injury, 2 studies
- Lung Diseases, Interstitial, 2 studies
- Pulmonary Fibrosis, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.